182 related articles for article (PubMed ID: 9475253)
1. A remarkable improvement of clinical manifestations in a breast cancer patient with widespread bone metastases after administration of pamidronate.
Kage K; Nagahama T; Sekine I; Maruyama M; Ogata E
Intern Med; 1997 Dec; 36(12):926-30. PubMed ID: 9475253
[TBL] [Abstract][Full Text] [Related]
2. [Two bedridden patients with bone metastases from breast cancer effectively treated with pamidronate therapy].
Kokufu I; Taniguchi H; Kim YH; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1751-4. PubMed ID: 11057329
[TBL] [Abstract][Full Text] [Related]
3. Delayed progression of bone metastases with pamidronate therapy in breast cancer patients: a randomized, multicenter phase III trial.
Conte PF; Giannessi PG; Latreille J; Mauriac L; Koliren L; Calabresi F; Ford JM
Ann Oncol; 1994; 5 Suppl 7():S41-4. PubMed ID: 7873461
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group.
Hortobagyi GN; Theriault RL; Porter L; Blayney D; Lipton A; Sinoff C; Wheeler H; Simeone JF; Seaman J; Knight RD
N Engl J Med; 1996 Dec; 335(24):1785-91. PubMed ID: 8965890
[TBL] [Abstract][Full Text] [Related]
5. Oral pamidronate in the prevention and treatment of skeletal metastases in patients with breast cancer.
van Holten-Verzantvoort AT; Papapoulos SE
Medicina (B Aires); 1997; 57 Suppl 1():109-13. PubMed ID: 9567363
[TBL] [Abstract][Full Text] [Related]
6. Bisphosphonate therapy in metastatic breast cancer.
Blomqvist C; Elomaa I
Acta Oncol; 1996; 35 Suppl 5():81-3. PubMed ID: 9142974
[TBL] [Abstract][Full Text] [Related]
7. [Bone metastases responsive to pamidronate therapy in breast cancer].
Oura S; Sakurai T; Yoshimura G; Tamaki T; Umemura T; Kokawa Y
Gan To Kagaku Ryoho; 1997 May; 24(7):865-8. PubMed ID: 9170527
[TBL] [Abstract][Full Text] [Related]
8. A randomized, double-blind, phase II, exploratory trial evaluating the palliative benefit of either continuing pamidronate or switching to zoledronic acid in patients with high-risk bone metastases from breast cancer.
Jacobs C; Kuchuk I; Bouganim N; Smith S; Mazzarello S; Vandermeer L; Dranitsaris G; Dent S; Gertler S; Verma S; Song X; Simos S; Cella D; Clemons M
Breast Cancer Res Treat; 2016 Jan; 155(1):77-84. PubMed ID: 26643085
[TBL] [Abstract][Full Text] [Related]
9. [Retardation of progression of bone metastasis in mammary carcinoma patients by intravenous pamidronate treatment: results of a randomized, controlled, multinational study].
Adamietz IA
Strahlenther Onkol; 1998 Aug; 174(8):438. PubMed ID: 9739387
[No Abstract] [Full Text] [Related]
10. Bisphosphonates for cancer patients: why, how, and when?
Body JJ; Mancini I
Support Care Cancer; 2002 Jul; 10(5):399-407. PubMed ID: 12136223
[TBL] [Abstract][Full Text] [Related]
11. Skeletal retention of bisphosphonate (pamidronate) and its relation to the rate of bone resorption in patients with breast cancer and bone metastases.
Cremers SC; Papapoulos SE; Gelderblom H; Seynaeve C; den Hartigh J; Vermeij P; van der Rijt CC; van Zuylen L
J Bone Miner Res; 2005 Sep; 20(9):1543-7. PubMed ID: 16059626
[TBL] [Abstract][Full Text] [Related]
12. [A case of multiple bone metastases from advanced breast cancer effectively treated with pamidronate].
Nakaguchi K; Furukawa J; Shingai T; Azama T; Yoshioka S; Katsumoto Y; Morimoto T; Okajima S; Sue F
Gan To Kagaku Ryoho; 1999 Sep; 26(10):1465-7. PubMed ID: 10500535
[TBL] [Abstract][Full Text] [Related]
13. Bisphosphonates for breast cancer.
Pavlakis N; Stockler M
Cochrane Database Syst Rev; 2002; (1):CD003474. PubMed ID: 11869664
[TBL] [Abstract][Full Text] [Related]
14. Disodium pamidronate in the treatment of bone metastases from breast cancer.
Colleoni M; Bochicchio AM; Nolè F; Bajetta E
Tumori; 1993 Oct; 79(5):340-2. PubMed ID: 8116078
[TBL] [Abstract][Full Text] [Related]
15. Clinical efficacy of bisphosphonate therapy for bone metastasis from breast cancer.
Oura S; Hirai I; Yoshimasu T; Kokawa Y; Sasaki R
Breast Cancer; 2003; 10(1):28-32. PubMed ID: 12525760
[TBL] [Abstract][Full Text] [Related]
16. Pamidronate infusions as single-agent therapy for bone metastases: a phase II trial in patients with breast cancer.
Tyrrell CT; Bruning PF; May-Levin F; Rose C; Mauriac L; Soukop M; Ford JM
Eur J Cancer; 1995 Nov; 31A(12):1976-80. PubMed ID: 8562151
[TBL] [Abstract][Full Text] [Related]
17. Comparative evaluation of markers of bone resorption in patients with breast cancer-induced osteolysis before and after bisphosphonate therapy.
Body JJ; Dumon JC; Gineyts E; Delmas PD
Br J Cancer; 1997; 75(3):408-12. PubMed ID: 9020487
[TBL] [Abstract][Full Text] [Related]
18. [A case of effective bisphosphonate therapy of sequential pamidronate and incadronate for bone metastases from breast cancer].
Kokufu I; Taniguchi H; Kim YH; Fukuda K; Yamamoto M; Yano T; Yamada K; Kitano H
Gan To Kagaku Ryoho; 2000 Aug; 27(9):1425-8. PubMed ID: 10969600
[TBL] [Abstract][Full Text] [Related]
19. [The evaluation of pamidronate therapy for bone metastases from breast cancer].
Nomizu T; Yabuta T; Katagata N; Watanabe F; Yamaki Y; Nihei M; Tsuchiya A; Takenoshita S; Abe R
Gan To Kagaku Ryoho; 2000 Nov; 27(13):2097-103. PubMed ID: 11103241
[TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial.
Rosen LS; Gordon D; Kaminski M; Howell A; Belch A; Mackey J; Apffelstaedt J; Hussein M; Coleman RE; Reitsma DJ; Seaman JJ; Chen BL; Ambros Y
Cancer J; 2001; 7(5):377-87. PubMed ID: 11693896
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
